Medical Access and Reimbursement in Bulgaria

Currently classified as a strictly controlled substance under Bulgarian drug‑scheduling laws (listed among high‑risk substances / List I) with no authorised medical use outside of approved clinical research. Possession, cultivation, distribution and manufacture are criminal offences subject to fines and imprisonment; any therapeutic use must be conducted only within formally authorised research/clinical trial frameworks under national law. # #

Currently classified as a strictly controlled/high‑risk substance under Bulgarian drug law (List I) and is prohibited outside of authorised scientific research; there is no routine medical or reimbursed therapeutic access. Criminal penalties apply for possession, distribution and manufacture; clinical research may be possible but requires formal approvals. # #

Esketamine nasal spray (Spravato®) is authorised at the EU level for treatment‑resistant major depressive disorder and related EU indications, after an EMA marketing authorisation (marketing authorisation valid throughout the EU, 18 December 2019) with specific safety and restricted‑use measures. The EMA product information and EPAR set out the approved indication (Spravato in combination with an oral antidepressant for adults with treatment‑resistant major depressive disorder) and specify supervised administration and risk‑mitigation measures. #.

In Bulgaria Spravato is listed in national pharmaceutical registries and appears on product listing pages with an established national price and an explicit note that it is paid by the National Health Insurance Fund (НЗОК), indicating it has been placed on the Positive Drug List and is eligible for NHIF reimbursement subject to national prescribing rules, HTA outcomes and any local restrictions or prior authorisation requirements. Local pricing/listing records show an approved national price and an NHIF payment status. Reimbursement and access in practice will be governed by Bulgarian HTA and NHIF rules (inclusion in the Positive Drug List, negotiated reference price, reimbursement rate, and any clinical eligibility criteria such as prior treatment failures and administration under supervised conditions). # #.

Operationally in Bulgaria this means: (1) Spravato requires prescription and administration in an appropriate clinical setting under the product's safety restrictions; (2) NHIF reimbursement is possible but subject to the Positive Drug List rules, HTA decision specifics and any negotiated conditions (reference price, co‑payment levels, and prior authorisation); and (3) clinicians and institutions must follow the product SmPC and any national REMS‑style or pharmacovigilance requirements when delivering treatment. #

Ketamine is a controlled substance in Bulgaria but retained and regulated as an approved medicinal product for legitimate medical uses (primarily as an anaesthetic/analgesic); it is available in healthcare settings under prescription and standard medicinal‑product controls. Its status as a regulated anesthetic/analgesic is distinct from the illicit market: licensed ketamine products are used in hospitals and clinics and are subject to controlled‑substance handling rules. # #.

Off‑label psychiatric use of ketamine (low‑dose intravenous or intranasal formulations for treatment‑resistant depression) is internationally practiced and discussed in Bulgarian clinical circles, but such off‑label psychiatric use in Bulgaria would require appropriate clinical governance, adherence to national prescribing rules and institutional policies, and typically is not a routinely NHIF‑reimbursed indication unless covered via specific local HTA/contracting pathways. Clinical adoption for psychiatric indications may therefore be limited by budget, institutional policy, and the absence of an authorised indication/reimbursement pathway for that specific indication. Practically: (1) licensed ketamine products are legally available for medical indications under prescription; (2) use for depression is off‑label and reimbursement depends on local payer/clinic decisions and HTA outcomes; and (3) any non‑authorised therapeutic use should be managed under formal institutional protocols and, where possible, within clinical research frameworks. #

Currently classified under Bulgaria's controlled substances framework with no authorised medical use outside approved research; possession, production or distribution is criminalised and therapeutic access is limited to formally authorised clinical trials. # #

Currently classified as a controlled/illegal substance in Bulgaria with no authorised medical or routine therapeutic access outside approved research; any use outside authorised clinical trials or licensed medical products is prohibited. # #

Currently classified as a controlled/illegal substance under Bulgarian law with no authorised medical use outside of formally approved research protocols; access for therapeutic purposes is not authorised in routine clinical practice. #

Although plant materials and ceremonial contexts raise complex legal questions in some jurisdictions, in Bulgaria ayahuasca‑associated controlled alkaloids (e.g., DMT) are scheduled and use outside authorised clinical research is not permitted; therefore ayahuasca ceremonies are not a lawful medical treatment and are subject to the same criminal controls as other scheduled substances. # #

Mescaline (and mescaline‑containing cacti preparations) is controlled under Bulgarian drug laws and has no authorised therapeutic use outside of approved clinical research; possession, manufacture and distribution are criminal offences. # #

Members of the 2C family (2C‑B/2C‑X derivatives) are scheduled/controlled in Bulgaria as part of List I/novel psychoactive substances regulation; there is no authorised medical use and access is limited to formally approved research contexts. Possession, distribution and production are criminal offences. # #